# US 2018/0021267 A1 · Compositions and methods relating to resveratrol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021267 A1
- Document ID: US20180021267A1
- Status: Published application
- Kind: A1
- Application number: 15/721,010
- Filed: 2017-09-29
- Published: 2018-01-25
- Earliest claimed: 2009-11-30
- Assignees: Wilmore Labs L.L.C
- Applicants: Wilmore Labs LLC
- Inventors: Otis L. Blanchard
- Web page: https://patentgrep.com/patent/US20180021267A1

## CPC

- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/006: {Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compositions and methods comprising resveratrol and uses thereof. Some embodiments include compositions and methods with increased bioavailability of resveratrol. Certain embodiments include compositions comprising resveratrol and a solubilizer. Particular embodiments include transmucosal delivery of resveratrol from the composition.

## Claims

### Claim 1

A pharmaceutical composition, comprising resveratrol and a solubilizer in solid or semi-solid form, wherein said solubilizer is selected from the group consisting essentially of an analog of ribose, arabanose, ribulose, deoxyarabanose, xylose, deoxyxylose, fructose, deoxyfructose, ribose, deoxyribose and mixtures thereof.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 comprising a binder.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2 wherein the binder is sucrose, gum Arabic, gum tragacanth, gelatin, starch, dextrose, or a mixture thereof.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the percentage weight of the solubilizer is in the range of about 2% to about 99% by weight of a dosage form of said pharmaceutical composition.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the percentage weight of the solubilizer is in the range of about 5% to about 95% by weight of a dosage form of said pharmaceutical composition.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein resveratrol comprises from about 1% to about 50% by weight of a dosage form of said pharmaceutical composition.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein resveratrol comprises from about 5 mg to about 1,000 mg resveratrol of a dosage form of said pharmaceutical composition.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein an amount of said resveratrol to solubilizer in a dosage form of said pharmaceutical composition is in the range of about 20 mg/g to about 100 mg/g.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1 in a dosage form selected from the group consisting of a tablet, a solid lozenge, a semisolid lozenge, a taffy, a thin film, a capsule, a patch, a gel, a bolus, a chewing gum, a paste, a syrup, and a freeze dried solid.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein the dosage form is a solid lozenge.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, comprising a dosage form having a coating.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11 wherein the coating is impermeable to light.

### Claim 13 (depends on 9)

The pharmaceutical composition of claim 9, wherein the amount of resveratrol in the dosage form is about 100 mg.

### Claim 14 (depends on 1)

The pharmaceutical composition of claim 1 in a dosage form suitable for bucal, sublingual, or gingival delivery.

### Claim 15 (depends on 1)

The pharmaceutical composition of claim 1, wherein the ratio of resveratrol to solubilizer in a dosage form of the pharmaceutical composition is in the range of about 5 mg/g to about 500 mg/g.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the ratio of resveratrol to solubilizer is in the range of about 20 mg/g to about 100 mg/g.

### Claim 17 (depends on 1)

The pharmaceutical composition of claim 1, comprising a sweetener, a thickener, a preservative, a coloring agent, a binder, a flavorant, a penetration enhancer, or a combination thereof.

### Claim 18 (depends on 1)

The pharmaceutical composition of claim 1 comprising a penetration enhancer selected from the group consisting of a bile salt, a surfactant, a fatty acid, a fatty acid derivative, a chelator, and chitosan.

### Claim 19 (depends on 1)

The pharmaceutical composition of claim 1 comprising a penetration enhancer.

### Claim 20 (depends on 2)

The pharmaceutical composition of claim 2 wherein the binder is sucrose.
